{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaqj5vuxpwm2fnttjtst2rwjip2zeea3yypn27spjjetjlosxqfey",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mgcfhrjw7zt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifu5764vmwkurx2m5ddo3rq5mnyo7qgw5n6celgvnrugspbyv54ye"
    },
    "mimeType": "image/webp",
    "size": 255800
  },
  "path": "/releases/2026/03/260304184215.htm",
  "publishedAt": "2026-03-04T21:14:30.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy. In clinical trials, the treatment zorevunersen cut seizures by as much as 91% while also improving quality of life for many patients. The therapy works by boosting the function of a key gene involved in nerve cell signaling. Encouraging results have led researchers to launch a larger Phase 3 trial.",
  "title": "New drug cuts seizures by up to 91% in children with rare epilepsy"
}